Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv-Reference-Cited by-同舟云学术

Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv

Published:2020-10-24 Issue:12 Volume:23 Page:1466-1476
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

MacDonald Karen¹,McBride Ali²³⁴,Alrawashdh Neda⁵,Abraham Ivo¹³⁴⁵⁶^ORCID

Affiliation:

1. Matrix45, Tucson, AZ, USA

2. Medical Center, Banner University, Tucson, AZ, USA

3. Cancer Center, University of Arizona, Tucson, AZ, USA

4. Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA

5. Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA

6. Department of Family and Community Medicine, College of Medicine, University of Arizona, Tucson, AZ, USA

Funder

Coherus BioSciences, Inc.

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2020.1833339

Reference45 articles.

1. National Comprehensive Cancer Network [Internet]. NCCN clinical practice guidelines in oncology. Hematopoietic growth factors. Plymouth (PA): NCCN; 2020 [cited 2020 July 6]. Available from https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf

2. Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012

3. Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy

4. Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

5. Prevention of Chemotherapy-Induced Febrile Neutropenia by Prophylactic Antibiotics Plus or Minus Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer: A Dutch Randomized Phase III Study

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer;Journal of Medical Economics;2024-04

2. Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma;Journal of Medical Economics;2024-04

3. On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status;Cancer Treatment and Research Communications;2024

4. Pharmacoeconomic analysis of using empegfilgrastim for the treatment of early and locally advanced HER2+ breast cancer in the Russian Federation;FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology;2023-12-30

5. The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region;Expert Opinion on Biological Therapy;2023-07-26